申请人:Taro Pharmaceutical Industries Ltd.
公开号:US20030018080A1
公开(公告)日:2003-01-23
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I
1
with an alkylating agent of structure III
2
in the presence of a basic catalyst in an aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbarbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.
本发明的一种N-烷氧基烷基化脲类的方法包括在无极性反应介质中,在碱性催化剂的存在下,将I1结构的脲类与III2结构的烷基化试剂反应。该脲类可以是5,5-二取代的巴比妥酸,或者可以是苯妥英、格乐酰胺和依托咪酰胺。烷基化试剂是磺酸酯。碱可以是氢化物或胺。首选的方法包括在二异丙基乙基胺的存在下,用甲氧甲基磺酸甲酯对5,5-二苯基巴比妥酸进行N-烷氧基烷基化反应,并分离出所得的N,N'-双甲氧甲基-5,5-二苯基巴比妥酸。本发明还涉及新的化合物N-甲氧甲基-5,5-二苯基巴比妥酸、N-甲氧甲基依托咪酰胺和N-甲氧甲基格乐酰胺,以及将它们用于治疗患者的方法。